Diffuse panbronchiolitis: not just an Asian disease: Australian case series and review of the literature by Anthony, MP et al.
Available online at http://www.biij.org/2009/4/e19 
doi: 10.2349/biij.5.4.e19 
biij 
Biomedical Imaging and Intervention Journal 
CASE REPORT 
Diffuse panbronchiolitis: not just an Asian disease: 
Australian case series and review of the literature 
M P Anthony
1, MBBS, S Singham
1, MBBS, LLB, B Soans
1, MBBS, MD, FRANZCR, 
G Tyler
2, FRACP 
1Department of Medical Imaging, John Hunter Hospital, Newcastle, Australia 
2Department of Respiratory Medicine, John Hunter Hospital, Newcastle, Australia 
Received 5 April 2009; received in revised form 1 May 2009; accepted 1 May 2009 
 
ABSTRACT 
Diffuse panbronchiolitis is a disease of obscure aetiology that is traditionally associated with Asian ethnicity. We 
propose  that  this  disease  also  occurs  in  Caucasians  and  the  incidence  in  this  population  is  greater  than  currently 
recognised. We further propose that high resolution computed tomography (HRCT) and response to macrolide therapy 
should be relied upon to make this diagnosis without verification by lung biopsy. In most circumstances, obtaining a 
biopsy for histopathology is not practical, and the disease may then be mistaken for other more common airway diseases. 
Accuracy of diagnosis is important as untreated disease is associated with a poor prognosis, and effective treatment is 
available.  We  report  four  out  of  a  series  of  cases  as  evidence  that  DPB  is  in  fact  more  common  in  the  Western 
population than is currently understood. © 2009 Biomedical Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
First  described  in  1969,  diffuse  panbronchiolitis 
(DPB)  is  a  chronic  inflammatory  disease  of  the  distal 
airways [1,2]. Patients present with a history of cough, 
large  volume  sputum  production  similar  to 
bronchiectasis, exertional dyspnoea, and chronic sinusitis. 
Physical signs include rales and rhonchi. Lung function 
tests demonstrate a mixed obstructive/restrictive pattern. 
Chest radiograph features may be non specific, with the 
presence  of  ill defined  small  nodular  shadows, 
hyperinflation, and in later stages, bronchiectasis. HRCT 
features  classically  include  small  centrilobular  nodules 
and branching linear opacities – the ‘tree in bud’ (TIB) 
appearance. Treatment consists of macrolide antibiotic in 
low dosage for 3 to 6 months. 
CASE REPORTS 
Case 1 
A  64 year old  Caucasian  female  non smoker 
presented in June 2004 with a 20 year history of non 
productive cough. There was no significant past medical 
or  exposure  history.  Previous  therapeutic  trials  of  a 
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combination  inhaler  containing  budesonide  and 
efermoterol, and omeprazole had been ineffective. 
Clinical examination, spirometry and flow volume 
loop were normal. Forced expiratory volume in 1 second 
(FEV1)  was  96%  predicted,  and  forced  vital  capacity 
(FVC)  was  125%  predicted.  A  bronchial  provocation 
with hypertonic saline challenge revealed a PD20 greater 
than  20  milli litres  (normal).  Serum  immunoglobulin 
levels were normal.  
HRCT  demonstrated  mild  bronchiectasis  in  the 
lower lobes, and diffuse centrilobular nodules. There was 
a scattered TIB appearance. 
There was complete resolution of symptoms when 
treated with erythromycin 250mg twice daily for three 
months. 
Case 2 
A  16 year old  Caucasian  Australian born  boy 
presented  in  March  2004  with  a  chronic  cough 
productive of yellow sputum. The cough began in early 
childhood and was initially intermittent but became more 
severe and persistent around the age of 11 years. There 
was no associated wheeze or breathlessness. The severity 
of  the  cough  gradually  increased.  His  symptoms  were 
attributed  to  asthma  and  he  received  asthma  therapy 
including  intermittent  oral  steroids  without  benefit  for 
several years. There was no history of smoking, dust nor 
fume exposure. 
He had a barrel chest, and had widespread bilateral 
crackles. There were no signs of pulmonary hypertension, 
and no clubbing. 
Spirometry  showed  mixed  restrictive  and 
obstructive change with an FEV1/FVC of 2.4/3.34 litres 
without acute reversibility (predicted 3.93/4.26). Sputum 
cultures grew haemophilus influenzae. No acid fast bacili 
was grown from repeated sputum cultures. There was a 
mild elevation in white cell count, but other blood tests 
were normal.  
HRCT  demonstrated  bilateral  bronchiectasis,  and 
diffuse centrilobular nodules predominantly affecting the 
mid and lower zones. There was diffuse TIB appearance.  
No improvement in symptoms resulted when treated 
with augmentin. A 6 week trial of erythromycin 250mg 
twice daily led to resolution of symptoms. There was an 
approximately  80%  clearance  of  the  above mentioned 
HRCT  findings  on  repeat  examination.  Spirometry 
improved to an FEV1/FVC of 4.36/4.94 litres.  
Case 3 
A  65 year old  Caucasian  Australian born  man 
presented in October 2004 with a 6 year history of cough 
productive  of  mucoid  sputum,  wheeze,  breathlessness 
and worsening pan sinusitis. There was a history of hay 
fever and gastro oesophageal reflux. He had experienced 
short term  improvement  with  a  number  of  courses  of 
antibiotics relapsing after each was complete. There was 
no  history  of  smoking,  occupational  dust  or  fume 
exposure.  Presenting  symptoms  had  been  attributed  to 
asthma but had not responded to asthma therapy. 
Clinical examination revealed generalised wheezing, 
but no other abnormality was detected. 
Spirometry  showed  mild  airflow  obstruction  with 
improvement  post  bronchodilator.  FEV1/FVC  pre 
bronchodilator  1.96/3.0  litres,  and  2.28/3.82  litres  post 
bronchodilator (predicted 2.85/3.64 litres).  
HRCT demonstrated mild basal bronchiectasis and 
basal TIB. 
There  was  an  improvement  in  spirometry 
(FEV1/FVC = 2.68/3.75 without bronchodilator response) 
and complete resolution of his symptoms after a 3 month 
course of erythromycin 250mg twice daily.  
   
(a)  (b) 
Figure 1  HRCT images of the lower chest in a 16 year old boy (Case 2) at presentation (A), and 8 weeks later 
after a 6 week course of erythromycin 250mg twice daily. The bilateral bronchiectasis and prominent 
centri lobular nodules with a tree in bud pattern shows marked improvement on the follow up scan. MP Anthony et al. Biomed Imaging Interv J 2009; 5(4):e19    3 
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Case 4 
A  73 year old  Caucasian  Australian born  woman 
presented  in  August  2003  with  6  months  of  cough 
productive  of  mucopurulent  sputum,  but  no  systemic 
symptoms. There was no significant past medical history, 
and no history of environmental exposures or of smoking. 
The cough had not responded to several courses of oral 
antibiotics including ciprofloxacin. 
Clinical  examination  and  spirometry  was  normal 
(FEV1 129 % predicted, FVC 130% predicted). Sputum 
cultures  grew  Pseudomonas  aeruginosa  and 
Mycobacterium  avium  complex  (MAC)  in  1  out  of 
3 samples.  Bronchoscopic  samples  grew  Pseudomonas 
aeruginosa  only.  There  was  no  immunoglobulin 
deficiency. 
The  chest  x ray  demonstrated  changes  of  right 
middle  and  lower  lobe  bronchiectasis  and  large  lung 
volumes.  HRCT  showed  bronchiectasis  in  the  middle 
and  lower  lobes,  and  some  atelectasis.  There  were 
diffuse  centrilobular  nodules.  The  left  lower  lobe  also 
demonstrated TIB appearance.   
A  2 week  course  of  ciprofloxacin  and  prednisone 
did  not  improve  her  symptoms.  A  3 month  course  of 
erythromycin 250mg twice daily led to resolution of her 
cough. 
DISCUSSION 
DPB is a chronic inflammatory disease of obscure 
aetiology affecting the distal airways, predominantly at 
the transition zone between the respiratory bronchioles 
and alveoli [1,2]. 
The disease typically occurs in the 2
nd to 5
th decade 
of life (average onset 40 years). The male: female ratio is 
1.4:2.1.  Two thirds  of  patients  are  non smokers  and 
patients have no particular history of inhalation of toxic 
fumes [3]. Whilst initially almost exclusively reported in 
Japan [4] there have now been sporadic cases reported in 
every continent [5]. The pathogenesis is still unclear, and 
thought to be related to both genetic and environmental 
factors. Sugiyama et al. [3] showed that 63% of patients 
possessed  the  HLA Bw54  antigen.  She  et  al. 
demonstrated increased frequency of class I HLA A11. 
HLA associated  major  histocompatibility  genes  are 
thought to be located in the HLA class I region between 
the HLA A and HLA B loci on chromosome 6p21.3 [6, 
7]. 
DPB is often confused  with other airway diseases 
characterised by chronic productive cough [8], including 
bronchiectasis, chronic bronchitis, and cystic fibrosis [9]. 
Due to this confusion and the importance of an accurate 
diagnosis, the diagnosis of  DPB has often relied upon 
histopathologic confirmation. Pathologic criteria include 
1) diffuse, bilateral, chronic inflammatory airway disease; 
2) predominant involvement of the walls of respiratory 
bronchioles  and  adjacent  centrilobular  regions;  and  3) 
interstitial  accumulation  of  foamy  macrophages  [10]. 
Typical features seen include thickening of the walls of 
the respiratory bronchioles, transmural and peribronchial 
infiltration by lymphocytes, plasma cells, and histocytes 
[11]. The inflammatory infiltrate destroys the bronchiolar 
epithelium  and  extends  to  peribronchiolar  spaces,  but 
most of the alveoli are unaffected [12]. The characteristic 
‘unit  lesion’  of  DPB  described  by  Kitaichi
  [13] 
incorporates some of these features, and is considered to 
histologically distinguish DPB from a number of other 
entities  including  chronic  bronchitis,  cystic  fibrosis, 
Mycoplasma  pneumonia  and  cryptogenic  organising 
pneumonia [14].
  
There are obvious restraints in the ability to always 
obtain a biopsy for diagnosis and an increasing reliance 
on clinical and radiologic findings should be encouraged. 
A  plain  chest  X Ray  (CXR)  reveals  bilateral,  diffuse, 
small  (<5mm)  nodular  shadows  predominantly  in  the 
lower field of the lung with hyperinflation. In advanced 
cases,  ring shaped  or  tram line  shadows  appear, 
indicating bronchiectasis.  
By  contrast,  the  HRCT  features  of  diffuse 
panbronchiolitis – given the appropriate clinical setting – 
can  be  near  pathognomonic  [15],  and  are  more 
representative  of  the  pathologic  process  [16].  In 
advanced stages, multiple cystic lesions predominate in 
the  lower  lung  fields  and  are  accompanied  by  dilated 
proximal bronchi  showing the appearance of extensive 
bronchiectasis.  These  findings  extend  from  the 
respiratory  bronchioles  to  the  proximal  airways  [17]. 
Nodular  shadows  are  distributed  in  a  centrilobular 
fashion, often extending to small, branching linear areas 
of attenuation (“TIB” pattern). Peripheral air trapping is 
usually  confirmed  in  expiratory  films.  Dilatation  of 
airways  and  bronchial  wall  thickening  are  present. 
Mosaic oligoemia is usually absent [12]. 
The  natural  history  of  DPB  is  progressive 
respiratory  failure  marked  by  chronic  and/or  frequent 
episodes  of  superimposed  bacterial  infection.  The 
capacity  for  gas  exchange  is  reduced,  which  causes 
progression  of  hypoxaemia,  and  later,  hypercapnia. 
Pulmonary hypertension develops and is associated with 
the development of cor pulmonale and ultimately death 
within 5 years for up to 20% of patients [13]. However, 
the cases described above may lead to the conclusion that 
the disease is less severe in Caucasians . These patients 
had  persistent  symptoms  for  several  years  without 
serious impairment of lung function. 
Appropriate management with a low dose macrolide 
antibiotic  such  as  erythromycin  (200 600mg  daily),  is 
well recognised to significantly alter the course of the 
disease  [18],  resulting  in  improved  symptoms  and 
pulmonary  function  tests,  reduced  hypoxaemia, 
improved radiographic appearances, and usually cure and 
improved  survival  [19].  It  has  been  found  that  both 
serum  and  sputum  erythromycin  levels  with  treatment 
are actually below the minimum inhibitory concentration 
for  the  common  superinfecting  organisms,  and  it  is 
postulated that the mechanism of action of erythromycin 
is related to anti inflammatory and immunomodulatory 
effects [20, 21], rather than to its antimicrobial properties 
[22]. MP Anthony et al. Biomed Imaging Interv J 2009; 5(4):e19    4 
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Nishimaki  et  al.  propose  that  anti inflammatory 
effects, including the inhibition of GM CSF production 
from monocytes, lung fibroblasts and bronchial epithelial 
cells and the acceleration of neutrophil apoptosis by the 
action of macrolide therapy, is what leads to improved 
survival  [23].  Studies  show  an  interference  with 
neutrophil  chemotaxis  by  erythromycin,  and  resultant 
lower neutrophil levels in broncho alveolar lavage fluid 
samples. In addition, macrolides reduce the presence of 
activated  T lymphocytes  at  the  site  of  inflammation, 
promoting  T cell  apoptosis  via  the  down regulation  of 
anti apoptotic  Bcl 2  protein  family  in  DPB  which  are 
present in high levels in such patients [24]. 
CONCLUSION 
A lack of familiarity with the diagnosis of DPB in 
Western countries has led to under diagnosis and failure 
to  treat  such  cases  [25,  26].  In  view  of  the  dramatic 
effectiveness of treatment, and that the treatment itself is 
very specific, the diagnostic features of DPB need to be 
recognised early. Fitzgerald et al. [5] suggest that if the 
appropriate  clinical,  physiologic,  and  radiological 
features  are  present,  then  lung  biopsy  is  usually 
unnecessary,  and  a  therapeutic  trial  of  a  macrolide 
antibiotic is appropriate. The reported cases illustrate that 
this  approach  is  successful.  These  cases  also  highlight 
that,  in  Caucasians,  the  disease  may  be  less  severe. 
However,  treatment  can  lead  to  symptom  control. 
Improved awareness of the disease should lead to higher 
rates of diagnosis and, therefore, improved treatment of 
such patients. 
ABBREVIATIONS 
●  DPB   diffuse panbronchiolitis 
●  HRCT  high resolution computed tomography 
●  TIB  tree in bud 
●  FEV1  forced expiratory volume in 1 second 
●  FVC   forced vital capacity 
●  CXR  chest X Ray 
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